Bg Medicine Stock Fundamentals
BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
BG Medicine fundamentals help investors to digest information that contributes to BG Medicine's financial success or failures. It also enables traders to predict the movement of BGMD Pink Sheet. The fundamental analysis module provides a way to measure BG Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BG Medicine pink sheet.
BGMD |
BG Medicine Company Current Valuation Analysis
BG Medicine's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BG Medicine Current Valuation | 545.97 K |
Most of BG Medicine's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BG Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, BG Medicine has a Current Valuation of 545.97 K. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 99.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
BG Medicine Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BG Medicine's current stock value. Our valuation model uses many indicators to compare BG Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BG Medicine competition to find correlations between indicators driving BG Medicine's intrinsic value. More Info.BG Medicine is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BG Medicine's earnings, one of the primary drivers of an investment's value.BGMD Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BG Medicine's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BG Medicine could also be used in its relative valuation, which is a method of valuing BG Medicine by comparing valuation metrics of similar companies.BG Medicine is currently under evaluation in current valuation category among its peers.
BGMD Fundamentals
Return On Equity | -9.03 | ||||
Return On Asset | -0.76 | ||||
Operating Margin | (2.86) % | ||||
Current Valuation | 545.97 K | ||||
Shares Outstanding | 11.37 M | ||||
Number Of Shares Shorted | 630.05 K | ||||
Price To Earning | (0.06) X | ||||
Price To Sales | 0.35 X | ||||
Revenue | 1.57 M | ||||
Gross Profit | 1.06 M | ||||
EBITDA | (4.39 M) | ||||
Net Income | (5.3 M) | ||||
Cash And Equivalents | 1.52 M | ||||
Cash Per Share | 0.14 X | ||||
Debt To Equity | 5.31 % | ||||
Current Ratio | 1.65 X | ||||
Book Value Per Share | (0.17) X | ||||
Cash Flow From Operations | (3.67 M) | ||||
Short Ratio | 2.66 X | ||||
Earnings Per Share | (0.72) X | ||||
Target Price | 1.4 | ||||
Beta | 83.44 | ||||
Market Capitalization | 545.97 K | ||||
Total Asset | 2.13 M | ||||
Retained Earnings | (161.49 M) | ||||
Working Capital | 771 K | ||||
Current Asset | 1.95 M | ||||
Current Liabilities | 1.18 M | ||||
Net Asset | 2.13 M |
About BG Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BG Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BG Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BG Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG MEDICINE operates under Medical Instruments Supplies classification in the United States and is traded on PNK Exchange. It employs 5 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |